Heart Failure (HF)
Patient Condition
HFrEF (ischemic cardiomyopathy), LVEF 30%, NYHA class II-III, cardiac function did not recover after anterior wall myocardial infarction. After optimized drug treatment, LVEF was still lower than 35%, so he was enrolled in the clinical trial of intracardiac injection of autologous bone marrow mesenchymal stem cells (MSC).
Treatment Timeline
| Phase | Details | Date |
|---|---|---|
| Clinical trial screening | ||
| Stem cell intracardiac injection | ||
| postoperative monitoring | ||
| follow-up assessments |
Treatment Outcome
| before | LVEF 30%, NYHA II-III, scar area covering 28% of left ventricle, 6-minute walking distance of 320m |
|---|---|
| after | LVEF 42%, NYHA class II, scar area reduced to 20%, 6-minute walk distance of 430m |
| highlight | After intracardiac injection of autologous MSC, LVEF increased by 12%, and myocardial scar area decreased by 8%. It is safe and feasible. |